21 has become a leading strategy in curing HIV. Recently, single-cell screening experiments 22 have shown the drug synergy between two categories of biomolecules, Activators (AC) 23 and Noise Enhancers (NE): NE can amplify the reactivation of latent HIV induced by AC, 24 although NE itself cannot reactivate HIV latency. Based on an established LTR-two-state 25 effective model, we uncover two necessary conditions for this type of drug synergy: The 26 decreasing of the turning-on rate of LTR induced by NE is highly inhibited when 27 presented with AC; The timescale of LTR turning off without AC/NE presented should be 28 no slower than the timescale of Tat transactivation. Then we propose a detailed LTR-29 four-state mechanistic model with both AC/NE regulation kinetics and Tat transactivation 30 circuit. We show that, in order to achieve drug synergy, the system of HIV gene state 31 transition must operate out of thermodynamic equilibrium, which is caused by energy 32 input. The direction of energy input determines whether the inhibition of NE upon the 33 reactivation rate of LTR-off states (unbinding of RNAP) can be successfully prevented in 34 the presence of AC. The drug synergy can also be significantly enhanced if the energy 35
low basal expression rate. The rarely produced Tat protein complexes with 75 CDK9 and CyclinT1 to form the positive transcriptional elongation factor b 76 (pTEFb). pTEFb can bind to the transactivation response element (TAR) on 77 the initially transcribed part of the HIV mRNA and remodel downstream 78 nucleosomes. This remodeling assists the elongation of the mRNA, thus 79 forming positive feedback (7) (8) (9) . In addition, a bimodal gene expression 80 ("phenotypic bifurcation" (10)) pattern was found in the offspring of defective-81 HIV infected cells with initially intermediate expression (10). However, it was 82 reported that the cooperativity coefficient (Hill coefficient) of Tat is only one 83 (11), which means that the mean-field deterministic dynamics of HIV gene 84 expression is monostable. This is distinct from the genetic toggle switch of the 85 lambda phage regulatory loop with stronger feedback and bi-stable 86 deterministic dynamics (12), or an oscillatory network with negative feedback 87 and a limit cycle (13) . The deterministic dynamics of the HIV regulatory 88 network is insufficient to explain the observed bimodality, and a stochastic 89 description may be required. By combining the bimodality and noisiness of 90 HIV promoter gene expression, Weinberger et al. found that the bimodality 91 arises from a very slow rate of switching on LTR expression (10), resulting in 92 a much noisier dynamics than those observed for normal human promoters. 93
On the other hand, functions of certain Activators and Noise Enhancers are 94 partially known. For example, as Activators, TNF and prostratin can activate 95 the transcriptional factor NF-κB, and therefore antagonize HIV latency (14) (15) (16) . 96 Some of these Noise Enhancers, such as ethinyl estradiol, can influence HIV 97 expression through another transcriptional factor SP1 or the structural state of 98 chromatin (17, 18) . The molecular mechanisms of most noise enhancers are 99 still unclear, indicating the complicated regulation mechanism of HIV 100 dynamics. However, no matter how complex it is, what these activators or 101 noise enhancers regulated are just the rates between different gene/promoter 102 states described by TF binding or structural difference. Therefore, the 103 functions of Activators and Noise Enhancers can be analyzed by certain 104 minimal but general models. 105
Thermodynamic energy dissipation plays a crucial role in bioactivities and 106 bioreactions. General model considering the binding of multiple transcription 107 factors (TF) under thermodynamic equilibrium in prokaryotic cells and the 108 function that different pair TF interactions can achieve in gene expression of 109 cells was already studied extensively (19, 20) . However, in studies of 110 eukaryotic transcriptional dynamics, a non-equilibrium mechanism is found 111 necessary(21), and many far-from-equilibrium models have been proposed 112 (22) (23) (24) (25) . In addition to biomolecule synthesis and cell motility, the regulatory 113 function of a living cell, such as adaptation and precise control of oscillations 114 was also found highly dissipative (26, 27) . Hence, we are very curious about 115 whether certain energy input is necessary for this type of drug synergy. 116
In addition, in a self-positive-feedback gene regulatory network, the timescale 117 of DNA state transition, mRNA transcription, mRNA decay, protein translation, and protein decay, will influence the cell fate landscape and phenotype 119 transitions (28-30). Post-integration HIV gene expression is one example 120 system of the TF regulatory mechanism of gene expression with self-positive-121 feedback. Hence, we are also interested in how the timescales of gene-state 122 transition and protein dynamics influence the drug synergy. 123
In this essay, we first investigate an established LTR-two-state model and find 124 two necessary conditions for the synergy between AC and NE on reactivating 125 latently infected HIV: (i) AC inhibits NE's function of reducing the transition 126 rate on for the gene-state reactivation; (ii) the rate off for the promoter to turn 127 off is not slower than the rate for Tat transactivation when the promoter is 128 already turned on. We then propose an LTR-four-state model and prove that 129 the noise enhanced drug synergy is indeed a non-equilibrium phenomenon of 130 the regulation of HIV promoter LTR. We show that controlling the magnitude 131 and direction of the system energy input can deter NE from reducing the 132 turned-on rate of inactivated gene state in the presence of AC, which induces 133 the synergy between AC and NE on the LTR transcription. The drug synergy 134
can be significantly enhanced when we distribute the total energy input into 135 two specific different reactions. Moreover, we show that only when the 136 timescale of DNA unbinding RNAP ( off or unbindp ) is comparable to or faster 137 than the timescale of Tat transactivation at gene activated state, the synergy 138 of AC and NE on the transcription on genetic level can pass to the translation 139 on protein level in the Tat self-positive-feedback HIV system.
Materials and methods 141
To investigate the synergy between AC and NE, we first employ a well-142 established LTR-two-state model with Tat transactivation from the previous 143 study ( Figure 2A) (31), which is quantified by single-cell analysis (32) (33) (34) . 151
As assumed in (4), adding only AC to the system increases on , while adding 152 only NE reduces on and off simultaneously with their ratio fixed. We use 153 parameter inh to quantify the degree of AC's inhibition upon the NE-induced 154 reduction of on , which is defined as We propose a more detailed LTR-four-state model with both transcript 162 activation and Tat transactivation ( Figure 3A , Figure S2A ). As the HIV 163 promoter, LTR controls HIV protein expression after the HIV genome 164
integrates into the DNA of human CD4+ cells (35, 36) . In this model, there are 165 four different promoter states: LTR state is the free state; LTR* is the 166 activated state but without RNAP binding; LTR-P and LTR*-P are the 167 corresponding RNAP-bounded states. AC is assumed to promote LTR 168 transiting to the activated state LTR*, e.g., LTR bound with NF-κB, and LTR* 169 recruits RNA polymerase much easier than LTR itself, e.g., the NF-κB bound 170
to LTR acting as a Transcription Factor (TF) to recruit RNA polymerase 171 (RNAP) to LTR (37). Dar, Hosmane, Arkin, Siliciano and Weinberger (4) show 172 that the screened Noise Enhancers have no effect on post transcription. 173 Some NEs can increase transcription factors in cells, such as SP1 (17, 18) . 174
Similar to (4), we assume that NE can slow down the switching rates between 175
LTR and LTR-P. 176
We use the Markov jumping process to model the transition among LTR 177 states with AC and/or NE added ( Figure 3A ). The four states can mutually 178 transit: in the absence of AC, RNAP binds to LTR at a relatively slow rate 179 bindp [ ] and unbinds at a relatively fast rate unbindp ; LTR transit to LTR* 180 state at an extremely slow rate act without AC, but at a much higher rate 181 act ( ≫ 1) with AC presented; RNAP is recruited to LTR* at a higher rate 182 bindp , where is the attraction coefficient ( > 1); when NE (or Noise Suppressor, NS) is added, LTR will bind and unbind RNAP at slower (faster 184 for NS) rates ( bindp − , unbindp − ) with noise attenuation factor . Note 185 that the setup of the model showed in Figure 3A is under the assumption of 186 the detailed balance. We will analyze both the models with or without this 187 assumption in the following sections. 188
We also combine the LTR-four-state model with the transcription/translation 189 module without Tat transactivation to characterize the procedure of screening 190 AC and NE ( Figure 3B ). In screening experiments of AC and NE, the LTR-191 GFP vectors without Tat transactivation were used (4). For the LTR-GFP 192 vectors, with RNAP bond to LTR (i.e., LTR-P state or LTR*-P state), the 193 downstream DNA of LTR can be transcribed into mRNA at rate m , 194 independent of the GFP copy number. Then the mRNA can be translated into 195 protein at rate GFP . Also, mRNA and GFP will degrade at rate m and GFP , 196 respectively ( Figure 3B ). 197
In the experiments of testing the synergy between AC and NE on HIV latency In addition, previous experiments also certified that Tat transactivation could 210 stabilize HIV activation state autonomous from the host cellular state (31, 34) . 211
Based on this, we assume that Tat reduces the dissociating rate of RNAP 212 from LTR, , thereby stabilizing the HIV activation state ( Figure 3C S2C; see Supplementary Section 2.7 for more details).
Results 224
The LTR-two-state model with significant large can exhibit drug 225
synergy between NE and AC 226
We simulate the LTR-two-state model showed in Figure 2A We also find out that another necessary condition for NE having synergy with 238 AC is off being greater than 10 −2 hour −1 , which is larger than the 239 parameters used in previous studies (31). However, other important results 240
shown in previous literature, the bimodal distribution of phenotype bifurcation 241 (10) and HIV latency establishment operating autonomously from the host 242 cellular state (31), are not sensitive to the increasing of off (Figure S1G-I). 243
When off is no greater than 10 −2 , there is no synergy between AC and NE on 244 reactivating latent HIV ( Figure 2E ; Figure S1E ). However, if off is greater 245 than 10 −2 , then NE can have synergy with AC on reactivating latent HIV 246 Figure S1F ). Furthermore, the synergy between AC and NE will 247 increase with the inhibiting effect quantity inh > 0 only when off is sufficiently 248 large, such as off = 0.8 > 10 −2 (red line in Figure 2G ). There will be no 249 synergy between AC and NE with the inhibiting effect quantity inh > 0 if off < 250 10 −2 (red line in Figure 2E ). Actually, in a latent HIV system, off is more likely 251 to be larger than that previously used in literature. The above theory can be illustrated by our LTR-four-state model ( Figure 3A , 284 C, and Figure S2A , C) (See Supplementary Section 2.1,2.3 and 2.4 for 285 details). Under the detailed balance condition, on keeps the same when both 286 NE (or NS) and AC are added to the system ( ≫ 1, = 1 (or = −1)) 287 compared to when only AC is added ( ≫ 1, = 0) ( Figure 4A ; see 288
Supplementary Section 2.5 for details). Thus, the Detailed-Balanced LTR-289 four-state model predicts no synergy between NE and AC and predicts that 290 NS does not suppress the AC's function of increasing on (Figure 4A) , 291
contradicting the experimentally observed synergy between AC and NE 292 ( Figure 1B) (4) . 293
We couple the Detailed-Balanced LTR-four-state model with Tat 294 transactivation, and there is still no synergy between Noise Enhancer and 295
Activator illustrated by the reactivation ratio of latent HIV ( Figure 4B ; see 296
Supplementary Section 2.7 for details). Note that the reactivation ratio of HIV 297 is calculated dynamically during a finite time starting from the latent state, 298 which is different from the steady-state probability on . However, they are 299 closely related to each other, since they both indicate the degree of 300 reactivation for latent HIV. 301
In addition, we calculate the mean duration time (MDT) of both the LTR-off 302 states (LTR and LTR*) and the LTR-on states (LTR-P and LTR*-P) (See 303
Supplementary Section 2.8 for details). The reciprocals of the MDTs 304 calculated from the LTR-four-state model can be regarded as the effective 305 transition rates in the reduced LTR-two-state model with only the LTR-off and 306 LTR-on state. Then we find out that AC can shorten the MDT at LTR-off 307 states ( Figure S4E, Figure S4F ), and that NE can lengthen the MDT at both 308 LTR-on states and LTR-off states with their ratio fixed ( Figure 4C-D, S5G-H) .
These results are consistent with the assumptions of the LTR-two-state model 310 in the previous section. However, in this Detailed-Balanced model, the 311 effective inhibiting effect quantity inh defined through the effective transition 312 rates, always vanishes ( Figure 4E ; see Supplementary Section 2.9 for the 313 exact definition of inh ). This confirms the LTR-two-state model predictions, 314 that no synergy between AC and NE on reactivating latent HIV should be 315 observed when inh = 0. 316
Hence, for Noise Enhancers synergize with ACs, the regulation of HIV gene 317 expression must be a Non-Detailed-Balanced process with energy dissipation. 318
The direction of the cycle flux caused by energy input in the Non-319
Detailed-Balanced LTR-four-state model determines the synergy 320
Inside a living cell, continuous energy consumption is necessary for executing 321 different vital functions. We already know that systems with the drug synergy 322 must be energy dissipative, but how energy input, i.e., breaking the detailed 323 balance, influences the drug synergy remains poorly understood. 324
We mainly investigate how the cycle flux direction and the energy input 325 distribution, as the features of the non-equilibrium system, effect the synergy. 326
Breaking the detailed balance is equivalent to having non-vanishing cycle 327 fluxes. In our LTR-four-state model, the cycle fluxes can be either counter-328 clockwise or clockwise. Energy input can be distributed on one or more 329 reactions. Here, we first consider the case when energy input is only through one single reaction ( Figure 5A ; see Supplementary Section 2.2 and Table S2 -331 1 for details). In the real biological system, the energy input can be realized 332 through ATP hydrolysis or other reversible covalent modification (44). 333
We prove that the Non-Detailed-Balanced LTR-four-state model can produce 334 the drug synergy between NE and AC on on , if and only if the direction of 335 cycle flux is clockwise. Mathematical analysis (See Supplementary Section 336 2.10 for details) and numerical simulations illustrate the same phenomenon. 337
The model with counter-clockwise cycle flux predicts no synergy between NE 338 and AC on on or HIV latency reactivation, and no reduction of on or latent 339 HIV reactivation is observed when NS is added with AC ( Figure 5B ). On the 340 other hand, with clockwise cycle flux, the model predicts 100% of NE can 341 synergize with AC on on , and about 75% of NE synergize with AC on latent 342
HIV reactivation ( Figure 5C ). 50% (4 out of 8) of the ways to break the 343 detailed balance through a single reaction to produce a clockwise cyclic 344 probability flux predicts significant synergy (> 5%) on on between NE and AC 345 ( Figure 5C up panel) , and that NS reduces on with AC added. 25% (2 out of 346 8, increasing transition rate from LTR*-P to LTR-P or reducing transition rate 347 from LTR-P to LTR*-P) of the ways predicts significant synergy (> 5%) on 348 reactivation of latent HIV between NE and AC ( Figure 5C HIV, instead of a particular mechanism of a specific NE. 358
We also show that in the above cases producing significant drug synergy 359 between AC and NE, the clockwise cyclic probability flux always promotes 360 LTR turn on mainly through the LTR*-to-LTR*-P pathway strengthened by AC 361 and turn off through the LTR-P-to-LTR pathway weakened directly by NE 362 (Figure 5D -E). It explains why NE can further amply the HIV latency 363 reactivation induced by AC, as long as the energy input provides clockwise 364 cyclic probability flux. 365
In addition, for the equilibrium system, the distribution of the dwell time at 366 LTR-off states is predicted to be monotonically decreasing and convex (45) 367 ( Figure S10, solid black lines) . The monotonicity or convexity can be 368 maintained for the non-equilibrium system with a low magnitude of energy 369 input (small disturbance from the equilibrium system) ( Figure S10, dashed red  370 line). However, as the magnitude of energy dissipation increases, the 371 nonmonotonicity or concavity of the distribution of dwell time could appear, 372 similar to the phenomenon of phase transition ( Figure S10D, H, dotted red  373 line, and solid red line).
The LTR-four-state model with distributed energy input may achieve 375
much stronger synergy than that with energy input only on a single 376 reaction 377
One possible strategy, through which strong synergy can be achieved, is to 378 drive the LTR promoter to turn on mostly through the LTR-to-LTR*-to-LTR*-P 379 pathway, whose rate can be significantly increased by AC, and to turn off 380 mostly through the LTR*P-to-LTR-P-to-LTR pathway ( Figure 5D-E) , whose 381 rate can be distinctly decreased by NE. This way, the promoter is more likely 382 to transit to the state LTR-P rather than the state LTR* once it is at the state 383 LTR*-P. Here, we build an EITST (Energy Input on the Two Specific 384
Transition rates) LTR-four-state model, in which part of the energy input 385 reduces the transition rate from LTR*-P to LTR* ( 2 ) and the other part 386 increases the transition rate from LTR*-P to LTR-P ( 1 ) ( Figure 6A ; see 387
Supplementary Section 2.2 for details), with the total energy fixed ( 1 + 2 = 388
). 389
We find that there is an optimal energy input distribution ( 1 = 1.8, 2 = 8.2) 390
for the system to perform the strongest synergy between AC and NE on on 391 ( Figure 6B ). The drug synergy on HIV latency reactivation dependent on the 392 energy input distribution is qualitatively quite similar. (Figure 6C) . Overall, the 393 certain distributed energy input with 0 < 1 < 10 may achieve stronger 394 synergy than that on only a single reaction ( 1 = 0 or 1 = 10). Without loss of generality, we set 1 = 5, 2 = 5 for the EITST LTR-four-state model, and all 396 the following simulation results are based on this value. 397
In such a Non-Detailed-Balanced model, simulation results of adding AC or 398 NE alone with GFP present are consistent with the drug screening 399 experimental data, that AC increases LTR mean expression level and NE 400 increases LTR expression noise ( Figure 6D-E, Figure 1B) . 401
The synergy between Noise Enhancer and Activator on both on ( Figure 6G ) 402 and HIV latency reactivation ( Figure 6H ) are observed and much stronger 403 than the scenario where energy input is only on a single reaction. Noise 404
Enhancer can increase the HIV latency reactivation from approximately 7% 405 when Activator is already added to 13% when both are added ( Figure 6H) . 406
These numbers are quite similar to the best cases observed in experiments 407 with prostratin as AC (experimental data from Figure 3A in (4) ). And Noise 408 suppressor reduces the AC-induced HIV latency reactivation from 7% to less 409 than 1% ( Figure 6H ). This synergy between AC and NE on both on and HIV 410 latency reactivation is found to be positively correlated with the magnitude | | 411 of the energy input, but will reach maximum (for on ) and saturation (for HIV 412 latency reactivation) when | | is getting sufficiently large ( > 5) ( Figure S6A-413   B ). In addition, the synergy is found to be positively correlated with the noise 414 of NEs ( Figure S6C ), this is also consistent with the experimental data ( Figure  415 3B in (4)).
states. Different from the Detailed-Balanced situation, NEs can lengthen the 418
MDT at the LTR-on states more significantly than lengthen the MDT at the 419 LTR-off states (Figure 6F, Figure S7C-F) . Further, the effective inhibiting 420 parameter inh ≈ 1 > 0 (See Supplementary Section 2.9 for the exact 421 definition of this effective parameter) means that AC does inhibit NE's function 422 of reducing the transition rate from the LTR-off states to the LTR-on states 423 ( Figure 6F ). These simulation results verified the conclusion we made in the 424 LTR-two-state model, that NE can synergize with AC and NE on reactivating 425 latent HIV only when inh > 0. Now we know that AC's inhibiting NE's function 426 of reducing effective on is achieved by the clockwise cycle flux driven by the 427 energy input. 428
However, same as in the LTR-two-state model, Noise Enhancer can amplify 429
Activator's reactivating latent HIV only if unbindp (equivalent to off in the 430 LTR-two-state model) is greater than 10 −2 ( Figure S8A ). To explain this 431 necessary condition, we analyze the timescale of Tat transactivation 432 dynamics and the timescale of LTR transitions. We find that it takes about 433 0 ≈ 20 hours on average for Tat transactivation and then LTR can maintain 434 the activated state for a long time ( Figure S8B and LTR*-P-Tat as modeled in the previous study (31). In the LTR-six-state 489 model, the same synergy can be predicted ( Figure S9, Supplementary  490 Section 2.4). Hence, our uncovered non-equilibrium mechanism of drug 491 synergy is not dependent on the specific Tat positive feedback mechanism. 492
The synergy that we studied here does not require cooperative binding 493 between the two categories of drugs (AC and NE or NS), which is essentially 494 different from the drug synergy based on classical equilibrium binding 495 mechanism. It might be the reason why the tested drug synergies in vitro 496 often fail in vivo. The nonequilibrium model proposed here provides a new 497 perspective to understand the drug synergy mechanism. 498 499
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Each group of x-axis represents the Non-Detailed-Balanced model with the 744 corresponding transition rate multiplying by ( > 0 for orange groups, < 745 0 for blue groups). (See Table S2 
